Literature DB >> 7750686

[Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal].

V Baty1, B Denis, C Goudot, V Bas, P Renkes, M A Bigard, P Boissel, P Gaucher.   

Abstract

Acute hepatitis related to psychotropic drugs has been rarely reported with anxiolytic treatments. Alpidem (Ananxyl) is a new imidazopyridine derivative with anxiolytic properties which was launched in October 1991. Several cases of acute hepatitis, some severe, were described with this drug and its liver toxicity was questioned. Results of a study monitoring drug side-effects caused this drug to be withdrawn from the market for one year. We report four cases of acute hepatitis and discuss the role of alpidem. All but one case were presented as severe acute hepatitis with hepatic failure. One patient ran a fulminant course and died despite liver transplantation. The mechanism of liver toxicity remains unclear.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7750686

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  3 in total

1.  Hepatotoxicity associated with zolpidem treatment.

Authors:  D Karsenti; P Blanc; Y Bacq; E H Metman
Journal:  BMJ       Date:  1999-05-01

Review 2.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Anxioselective anxiolytics: on a quest for the Holy Grail.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2012-09-14       Impact factor: 14.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.